Advertisement
ROCHELLE, Va., May 15, 2019 /PRNewswire-PRWeb/ -- NDA Partners Chairman Carl Peck, MD, announced today that Johannes N. van den Anker, MD, PhD, a prominent neonatal and pediatric clinical pharmacologist and expert in pediatric and neonatal clinical trials and therapies, has joined the firm as an Expert Consultant.
Dr. van den Anker is Vice Chair of Pediatrics for Experimental Therapeutics, the Evan and Cindy Jones Chair in Pediatric Clinical Pharmacology, and serves as Director of the Division of Clinical Pharmacology at Children's National Medical Center (Washington, DC). He is Professor of Pediatrics, Pharmacology & Physiology, and Genomics and Precision Medicine at The George Washington University (Washington, DC). He is also the Eckenstein-Geigy Distinguished Professor of Pediatric Pharmacology and Department Chair of Pediatric Pharmacology and Pharmacometrics, University Children's Hospital (Basel, Switzerland), and Adjunct Professor of Medicine, Pediatrics, Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine (Baltimore, MD), and Adjunct Faculty, Intensive Care and Department of Surgery, Erasmus MC-Sophia Children's Hospital (Rotterdam, the Netherlands). In addition to his research positions, Dr. van den Anker serves as the part-time Chief Medical Officer of ReveraGen BioPharma.
Dr. van den Anker formerly served as Director, Division of Neonatology at Sophia Children's Hospital and as Director, Division of Pediatric Clinical Pharmacology and Medical Toxicology, at Columbus Children's Hospital (Columbus, Ohio).
"Dr. van den Anker's extensive knowledge of pediatric and neonatal clinical pharmacology and expertise in pediatric and neonatal therapies and clinical trials makes him an outstanding resource for assisting our clients in the design and implementation of their pediatric development programs," said Dr. Peck. "We are delighted that he has joined NDA Partners team of Expert Consultants."
Dr. van den Anker received his medical degree and Doctorate in Pharmacology from Erasmus University Rotterdam in Rotterdam, the Netherlands. He completed his residency in Pediatrics and a fellowship in Neonatology at Sophia Children's Hospital in the Netherlands.
About NDA Partners NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.
Contact Earle Martin, Chief Executive Officer Office: 540-738-2550 MartinEarle(at)ndapartners(dot)com
SOURCE NDA Partners
Advertisement
Dr. van den Anker is Vice Chair of Pediatrics for Experimental Therapeutics, the Evan and Cindy Jones Chair in Pediatric Clinical Pharmacology, and serves as Director of the Division of Clinical Pharmacology at Children's National Medical Center (Washington, DC). He is Professor of Pediatrics, Pharmacology & Physiology, and Genomics and Precision Medicine at The George Washington University (Washington, DC). He is also the Eckenstein-Geigy Distinguished Professor of Pediatric Pharmacology and Department Chair of Pediatric Pharmacology and Pharmacometrics, University Children's Hospital (Basel, Switzerland), and Adjunct Professor of Medicine, Pediatrics, Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine (Baltimore, MD), and Adjunct Faculty, Intensive Care and Department of Surgery, Erasmus MC-Sophia Children's Hospital (Rotterdam, the Netherlands). In addition to his research positions, Dr. van den Anker serves as the part-time Chief Medical Officer of ReveraGen BioPharma.
Dr. van den Anker formerly served as Director, Division of Neonatology at Sophia Children's Hospital and as Director, Division of Pediatric Clinical Pharmacology and Medical Toxicology, at Columbus Children's Hospital (Columbus, Ohio).
"Dr. van den Anker's extensive knowledge of pediatric and neonatal clinical pharmacology and expertise in pediatric and neonatal therapies and clinical trials makes him an outstanding resource for assisting our clients in the design and implementation of their pediatric development programs," said Dr. Peck. "We are delighted that he has joined NDA Partners team of Expert Consultants."
Dr. van den Anker received his medical degree and Doctorate in Pharmacology from Erasmus University Rotterdam in Rotterdam, the Netherlands. He completed his residency in Pediatrics and a fellowship in Neonatology at Sophia Children's Hospital in the Netherlands.
About NDA Partners NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.
Contact Earle Martin, Chief Executive Officer Office: 540-738-2550 MartinEarle(at)ndapartners(dot)com
SOURCE NDA Partners
